GM2 Gangliosidosis Market is projected to reach USD 332 million by 2034

The global GM2 Gangliosidosis Market-covering Tay-Sachs disease, Sandhoff disease, and related GM2 deficiency disorders-was valued at USD 152 million in 2024 and is projected to reach USD 332 million by 2034, growing at a CAGR of 8.1% during 2025-2034. Market growth is driven by increasing research in gene therapy, better awareness of lysosomal storage disorders (LSDs), advancements in newborn screening, and growth of specialized centers for rare diseases.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70913

GM2 gangliosidosis is a fatal, inherited lysosomal disorder caused by deficiency of β-hexosaminidase A (Tay-Sachs) or both A and B enzymes (Sandhoff). This leads to toxic accumulation of GM2 gangliosides in neurons, resulting in progressive neurodegeneration. With no current cure, there remains an immense unmet need for disease-modifying therapies.

Key Market Highlights
• 2024 Market Size: USD 152 million
• 2034 Forecast: USD 332 million
• CAGR (2025-2034): 8.1%
• Largest Segment: Gene therapy candidates
• Fastest-Growing Segment: Early diagnosis & newborn screening programs

Epidemiology & Clinical Insights
1. Disease Spectrum
GM2 gangliosidosis includes:
• Tay-Sachs disease (TSD) - HEXA deficiency
• Sandhoff disease (SD) - HEXA & HEXB deficiency
• GM2 activator deficiency - rarest form
2. Prevalence
• Infantile form: most common and severe
• Estimated global incidence: 1 in 100,000-300,000 births
• Higher carrier rates in certain populations (Ashkenazi Jewish, French-Canadian, Cajun)
3. Clinical Presentation
• Developmental regression
• Neurodegeneration
• Hypotonia
• Seizures
• Cherry-red spot on retina
• Progressive loss of motor and cognitive function
4. Diagnostics
• Enzyme assays
• Genetic testing (HEXA, HEXB mutations)
• Neuroimaging
• Newborn screening (emerging)

Market Growth Drivers
1. Rapid Progress in Gene Therapy
AAV-based and lentiviral therapies targeting HEXA/HEXB deficiencies show strong potential.
2. Increasing Global Awareness & Screening
Expanded carrier screening and newborn screening programs improve early detection.
3. Strong Rare Disease Funding & Incentives
Orphan drug designations, fast-track approvals, and government support drive R&D.
4. Emerging CNS Drug Delivery Technologies
Novel delivery techniques (intrathecal, intraventricular, BBB-penetrating vectors) increase efficacy.
5. Expanded Access to Genetic Counseling
Growing network of rare disease centers supports early diagnosis and patient enrollment in trials.

Market Restraints
• Extremely rare prevalence limits large clinical trials
• High cost of gene therapies
• Challenges delivering therapies across the blood-brain barrier
• Limited long-term efficacy data

Market Opportunities
1. AAV9 & AAVrh10 Vector Gene Therapies
Promise improved CNS penetration and durable enzyme expression.
2. Substrate Reduction Therapy (SRT)
Oral small molecules reducing glycosphingolipid accumulation.
3. Enzyme Replacement Therapy (ERT) Innovation
Next-generation recombinant enzymes with improved CNS targeting.
4. CRISPR & Gene-Editing Platforms
Long-term correction of HEXA/HEXB mutations.
5. Combination Therapies
Potential synergy between gene therapy + SRT + neuroprotective treatments.

Segmentation Overview
By Disease Type
• Tay-Sachs disease
• Sandhoff disease
• GM2 activator deficiency

By Therapy Type
• Gene therapy (AAV-based, lentiviral)
• Substrate reduction therapy
• Enzyme replacement therapy
• Small molecule therapies
• Supportive/palliative care

By Patient Type
• Infantile
• Juvenile
• Adult-onset

By Diagnostics
• Molecular genetic testing
• Enzyme analysis
• Newborn screening panels

By End User
• Hospitals
• Rare disease centers
• Specialty clinics
• Research institutions

Explore Full Report here: https://exactitudeconsultancy.com/reports/70913/gm2-gangliosidosis-market

Regional Insights
North America - Largest Market
Advanced gene therapy R&D, NIH-funded trials, and strong rare disease infrastructure.
Europe - Strong Research Ecosystem
Germany, France, UK, and the Netherlands lead in genomics and LSD clinical trials.
Asia Pacific - Fastest Growing
Increasing investment in gene therapy manufacturing and rare disease diagnostics.
Latin America - Developing
Expanding access to genetic testing and newborn screening.
Middle East & Africa - Emerging
Improved rare disease awareness and expansion of tertiary care centers.

Competitive Landscape
Key companies and research institutions driving GM2 gangliosidosis therapy development include:
• Axovant Gene Therapies (Sio Gene Therapies) - AAV9-based AXO-AAV-GM2
• Passage Bio - PBGM01 (AAV-delivered gene therapy)
• CAMP4 Therapeutics - RNA-based gene upregulation
• Prevail Therapeutics (Eli Lilly)
• BioMarin
• Genzyme / Sanofi
• JCR Pharmaceuticals
• Academic collaborations (UMass, NIH, CHOP, McGill)
Focus areas include AAV gene delivery, BBB-penetrating vectors, enzyme replacement innovations, and neuroprotective strategies.

Recent Market Developments
• Promising early-stage results from AAV9 gene therapy trials
• FDA and EMA orphan drug designations for multiple pipeline candidates
• Growing use of intrathecal delivery for CNS targeting
• Expanded newborn screening proposals for GM2 disorders
• Increased global patient registry enrollment improving trial readiness

Future Outlook (2025-2034)
The GM2 Gangliosidosis Market will expand significantly as:
• Gene therapy becomes central to treatment
• Early diagnosis improves through newborn screening
• CRISPR and novel vectors progress into clinical use
• Global funding for rare diseases increases
By 2034, the market is expected to reach USD 332 million, driven by breakthrough innovation in gene therapy and strengthened rare disease infrastructure.

This report is also available in the following languages : Japanese (GM2ガングリオシドーシス), Korean (GM2 강글리오시도시스), Chinese (GM2神经节苷脂病), French (Gangliosidose GM2), German (GM2-Gangliosidose), and Italian (Gangliosidosi GM2), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/70913

Our More Reports:

GM1 Gangliosidosis Market
https://exactitudeconsultancy.com/reports/71034/gm1-gangliosidosis-market

Granzyme B Antibody Market
https://exactitudeconsultancy.com/reports/66261/granzyme-b-antibody-market

Granzyme H Antibody Market
https://exactitudeconsultancy.com/reports/66262/granzyme-h-antibody-market

Anti-Nestin Antibody Market
https://exactitudeconsultancy.com/reports/66265/anti-nestin-antibody-market

Anti-Neuropilin-1 Antibody Market
https://exactitudeconsultancy.com/reports/66266/anti-neuropilin-1-antibody-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.